Anupam Rasayan Q2 FY26 Earnings Analysis

- Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated. - Letter of Intents (LOIs) contributing around INR 450-500 crores this year, expected to double compared to last year. - Similar growth trajectory expected next year as many LOIs and contracts get commercialized and ramped up. - Pharma segment revenue grew 3x year-on-year, expected to continue strong growth supported by new molecule launches. - Performance materials segment projected to grow from double-digit contribution to 15-20% in the current year, reaching 20-25% in next 2-3 years. - Continued strong performance in pharma, polymer, and agrochemical segments. - Ongoing commercialization of molecules in specialty polymers and fluorochemicals with multinational collaborations expected to support sustained growth.

- Anupam Rasayan expects strong revenue growth of over 30% in FY '26 driven by all segments: agro, pharma, polymer, and personal care. - Pharma segment revenue has shown 3x growth YoY, with continued ramp-up of new molecules launched in the last 18–24 months. - Performance materials segment is expected to grow from double-digit contribution to 15-20% in FY '26 and 20-25% in the next 2-3 years. - EBITDA margin for Q1 FY '26 stood at 26.3% consolidated, with standalone margin at 31%, indicating healthy profitability. - The company aims to maintain EBITDA margins around 25-27% for incremental growth. - Profit after tax margin was 10% for Q1 FY '26. - Long-term focus on debt reduction and working capital optimization should strengthen financial health and support sustainable profit growth. - Management expressed confidence in delivering sustained and profitable growth moving forward.

- All planned capex projects have been completed, with plants commissioned and fully operational. - Two new plants have been commercialized, and trial runs are ongoing in one additional plant. - No major capex is planned or necessitated in the near term. - The company is focusing on leveraging existing manufacturing capacities to ramp up new molecule launches and orders. - Emphasis is on optimizing working capital rather than incurring significant new capital investments in FY '26.

- The company received INR 277.5 crores from a preferential issue in July 2025, of which INR 175 crores has already been used to repay term debt. - Currently, the company is long-term net debt free on a net term debt basis. - Debt-to-EBITDA ratio is less than 2, with management targeting to keep it below 2, aiming for around 1.5 or less. - Working capital utilization is expected to improve, with inventory rationalization and no major capex planned, which should help reduce debt further. - No explicit mention of new fundraising through debt or equity during the call beyond the preferential issue received in July 2025. - Operating cash flows are expected to assist in ongoing debt reduction.

- Current order book stands at INR 14,646 crores, including recently signed LOIs with Japanese and U.S.-based multinational companies. - LOIs largely cater to polymer (performance chemicals) and agrochemical segments. - Expected order inflow for the current year is around INR 450-500 crores, with plans to double the LOI contribution compared to last year. - Similar growth in LOI order book is expected next year as many contracts are commercializing and ramping up. - Collaboration with a Japan-based fluorochemical conglomerate involves multiple niche molecules, mainly in specialty polymers, with commercialization ramping up next year. - Order book alignment is strong across pharma, agrochemicals, polymers, and personal care segments, with pharma and polymer segments showing significant growth.